203 patents currently held
58 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jan 2027. from the record
Of the 58 now held by other companies, 9 name Humabs Biomed S.A. as their current owner, and 49 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
21
Ending by 2030
Jan 2027
Next term end
125
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Nov 2030 · High confidence
Also notable
Ends Jun 2035 · High confidence
Also notable
Ends Nov 2035 · High confidence
Targeted Binding Agents Against B7-H1
US 8,779,108
The most cited patent in this portfolio, cited by 166 later US patents, top 5% of utility patents granted in 2014 in our data. Protection runs to 2030.
Methods of Treatment with Antagonists Against PD-1 and PD-L1 in Combination with Radiation Therapy
US 10,092,645
Cited by 20 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
Binding Molecules Specific for CD73 and Uses Thereof
US 9,938,356
Cited by 23 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 16, 2026The maintenance fee for Pyrrolobenzodiazepine Conjugates (US 11,649,250) comes due Nov 16, 2026. Unpaid by May 17, 2027, it lapses early.
- 2 fees due Dec 2 to 6, 2026 · next Dec 2
- 3 fees due Jan 2 to 16, 2027 · next Jan 2
- 2 fees due Feb 6 to 28, 2027 · next Feb 6
- 4 fees due Mar 1 to 26, 2027 · next Mar 1
- 8 fees due Apr 3 to 29, 2027 · next Apr 3
- 5 fees due May 3 to 28, 2027 · next May 3
- 5 fees due Jun 15 to 30, 2027 · next Jun 15
- 2 fees due Jul 14 to 28, 2027 · next Jul 14
- 6 fees due Aug 9 to 27, 2027 · next Aug 9
- 5 fees due Sep 3 to 26, 2027 · next Sep 3
- 2 fees due Oct 30, 2027
Recent changes
- Nov 9Assignment recorded on 1 record: AstraZeneca UK Limited to MedImmune Limited Recorded Nov 9, 2026, executed Jul 30, 2024. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76692, frame 866.
- Nov 9Assignment recorded on 1 record: Reid, Fred and 2 others to MedImmune Limited Recorded Nov 9, 2026, executed Jul 30, 2024. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76692, frame 869.
- 5 of the patents on this record were granted since Aug 17, 2026
- 8 terms have ended since Aug 17, 2026
What they patent
The 5 largest of its 125 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Binding Molecules Specific for CD73 and Uses Thereof | 5 in force | to Dec 2037 |
| Antibodies to Amyloid Beta | 5 in force | to Apr 2034 |
| Targeted Binding Agents Against B7-H1 | 5 in force | to Jun 2031 |
| Neutralizing Anti-Influenza Binding Molecules and Uses Thereof | 4 in force | to Jun 2036 |
| Methods of Treatment with Antagonists Against PD-1 and PD-L1 in Combination with Radiation Therapy | 4 in force | to Jun 2035 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,670,837 | Non-Tumorigenic MDCK Cell Line for Propagating Viruses In force · High confidence | In force | High confidence | |
| US 8,846,032 | MDCK Cell Lines Supporting Viral Growth to High Titers and Bioreactor Process Using the Same In force · High confidence | In force | High confidence | |
| US 9,005,620 | Compounds In force · Medium confidence | In force | Medium confidence | |
| US 8,008,443 | Modulation of Antibody Effector Function by Hinge Domain Engineering In force · High confidence | In force | High confidence | |
| US 8,666,778 | Systems and Methods for Processing Requests for Pharmaceuticals That Require Insurer Preapproval In force · Medium confidence | In force | Medium confidence | |
| US 7,790,655 | Cell Display of Antibody Libraries In force · High confidence | In force | High confidence | |
| US 7,790,434 | Methods and Compositions for Expressing Negative-Sense Viral RNA in Canine Cells In force · High confidence | In force | High confidence | |
| US 9,176,129 | Protein Scaffolds In force · High confidence | In force | High confidence | |
| US 8,137,670 | Method of Identifying Membrane Ige Specific Antibodies and Use Thereof for Targeting Ige Producing Precursor Cells In force · High confidence | In force | High confidence | |
| US 9,193,789 | Anti-Icos Antibodies and Their Use in Treatment of Oncology, Transplantation and Autoimmune Disease In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 203: 58 patents in force now held by others · 217 patents ended · 144 applications pending · 367 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.